Alto Neuroscience publishes corporate presentation on precision psychiatry, biomarker-driven brain drug pipeline

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00
  • Alto Neuroscience outlined a biomarker-driven precision psychiatry strategy, targeting patient selection to improve response rates and reduce late-stage development risk.
  • Lead program ALTO-207 for treatment-resistant depression remains in Phase 2b, with topline data expected in 2H 2027; Phase 3 initiation planned by early 2027.
  • ALTO-300 for major depressive disorder is in Phase 2b, with topline data expected in 1H 2027; ALTO-208 for bipolar depression is in Phase 2b, with topline data expected mid-2027.
  • ALTO-207 combines pramipexole with ondansetron, aiming to improve tolerability and enable faster titration; Phase 2a results cited an average 4.1 mg/day pramipexole dose reached in 8 days with a Week 8 MADRS placebo-adjusted reduction of 8.2 points.
  • Company projected expected cash runway through 2028, citing more than 600 patients dosed across studies and four late-stage data readouts over roughly next three years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.